Given Wegovy’s success and record-high sales, a wave of investments has gone into the obesity space over the last couple of ...

Chris Schott, an analyst from J.P. Morgan, maintained the Buy rating on Eli Lilly & Co (LLY – Research Report). The associated price target ...

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...

A new technology is disrupting the economy. Even experts don’t entirely understand how it works, its full range of uses and ...

Zepbound (tirzepatide) is reshaping the competitive landscape in obesity treatment, challenging Novo Nordisk A/S' (NYSE:NVO) ...

Since its debut, Zepbound has expanded its scope beyond ... Over 400 companies are now developing obesity therapies inspired by Wegovy's success. The drug is also approved for managing type ...